Revolution Medicines Inc (RVMD)
40.20
+1.01
(+2.58%)
USD |
NASDAQ |
May 03, 16:00
40.20
0.00 (0.00%)
After-Hours: 20:00
Revolution Medicines Research and Development Expense (Quarterly): 148.48M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 148.48M |
| September 30, 2023 | 107.74M |
| June 30, 2023 | 97.98M |
| March 31, 2023 | 68.95M |
| December 31, 2022 | 66.13M |
| September 30, 2022 | 69.46M |
| June 30, 2022 | 61.00M |
| March 31, 2022 | 56.49M |
| December 31, 2021 | 53.68M |
| September 30, 2021 | 46.47M |
| June 30, 2021 | 45.94M |
| Date | Value |
|---|---|
| March 31, 2021 | 40.86M |
| December 31, 2020 | 37.01M |
| September 30, 2020 | 34.87M |
| June 30, 2020 | 32.92M |
| March 31, 2020 | 27.46M |
| December 31, 2019 | 27.49M |
| September 30, 2019 | 22.96M |
| June 30, 2019 | 20.12M |
| March 31, 2019 | 21.19M |
| December 31, 2018 | 18.18M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
20.12M
Minimum
Jun 2019
148.48M
Maximum
Dec 2023
56.10M
Average
46.47M
Median
Sep 2021
Research and Development Expense (Quarterly) Benchmarks
| Cutera Inc | 4.564M |
| BioSig Technologies Inc | 1.176M |
| TRACON Pharmaceuticals Inc | 1.494M |
| Zentalis Pharmaceuticals Inc | 51.56M |
| Day One Biopharmaceuticals Inc | 37.35M |